3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Prostatic Intraepithelial Neoplasia
1
Neoplasms
1
Eye Diseases
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Cardiovascular Diseases
1
Interventions
pembrolizumab
28
Docetaxel
21
Gemcitabine
19
Nivolumab
15
Paclitaxel
13
Prednisone
12
Leuprolide
11
pazopanib
10
Radiotherapy
10
Cisplatin
10
Sunitinib
9
Sorafenib
9
Ipilimumab
8
Blood Specimen Collection
8
Bevacizumab
8
avelumab
7
atezolizumab
7
Therapeutics
7
Thalidomide
7
Cyclophosphamide
7
Carboplatin
7
Standard of Care
6
Radiation
6
Mitomycin
6
Interleukin-2
6
Cetuximab
6
Axitinib
6
padeliporfin
5
enzalutamide
5
cemiplimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Geritol
×
Genitourinary
×
Clear all
NCT00270647
2018-02-28
PHS II
Brigham and Women's Hospital
Phase NA
Completed
14,641 enrolled